A detailed history of Pnc Financial Services Group, Inc. transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Pnc Financial Services Group, Inc. holds 877 shares of SAGE stock, worth $5,025. This represents 0.0% of its overall portfolio holdings.

Number of Shares
877
Previous 381 130.18%
Holding current value
$5,025
Previous $4,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$7.02 - $13.08 $3,481 - $6,487
496 Added 130.18%
877 $6,000
Q2 2024

Aug 09, 2024

SELL
$10.58 - $17.9 $3,671 - $6,211
-347 Reduced 47.66%
381 $4,000
Q1 2024

May 10, 2024

SELL
$18.62 - $26.95 $4,655 - $6,737
-250 Reduced 25.56%
728 $13,000
Q4 2023

Feb 09, 2024

SELL
$17.1 - $22.26 $393 - $511
-23 Reduced 2.3%
978 $21,000
Q3 2023

Nov 13, 2023

BUY
$16.75 - $48.98 $10,569 - $30,906
631 Added 170.54%
1,001 $20,000
Q2 2023

Aug 11, 2023

BUY
$40.65 - $59.54 $284 - $416
7 Added 1.93%
370 $17,000
Q3 2022

Nov 10, 2022

SELL
$32.28 - $43.27 $484 - $649
-15 Reduced 3.97%
363 $14,000
Q2 2022

Aug 12, 2022

SELL
$27.52 - $37.99 $8,531 - $11,776
-310 Reduced 45.06%
378 $12,000
Q1 2022

May 12, 2022

SELL
$30.71 - $45.71 $4,575 - $6,810
-149 Reduced 17.8%
688 $22,000
Q4 2021

Feb 11, 2022

BUY
$37.06 - $47.11 $3,224 - $4,098
87 Added 11.6%
837 $35,000
Q3 2021

Nov 05, 2021

SELL
$40.26 - $57.37 $12,400 - $17,669
-308 Reduced 29.11%
750 $33,000
Q2 2021

Aug 06, 2021

SELL
$54.88 - $79.29 $603 - $872
-11 Reduced 1.03%
1,058 $60,000
Q1 2021

May 07, 2021

BUY
$70.65 - $96.76 $14,907 - $20,416
211 Added 24.59%
1,069 $80,000
Q4 2020

Feb 12, 2021

BUY
$58.41 - $89.06 $2,862 - $4,363
49 Added 6.06%
858 $74,000
Q3 2020

Nov 06, 2020

BUY
$41.13 - $62.45 $2,344 - $3,559
57 Added 7.58%
809 $49,000
Q2 2020

Aug 07, 2020

BUY
$25.95 - $43.15 $51 - $86
2 Added 0.27%
752 $31,000
Q1 2020

May 08, 2020

BUY
$26.15 - $77.24 $10,852 - $32,054
415 Added 123.88%
750 $21,000
Q4 2019

Feb 07, 2020

SELL
$60.18 - $154.77 $21,724 - $55,871
-361 Reduced 51.87%
335 $24,000
Q3 2019

Nov 08, 2019

BUY
$140.29 - $189.96 $37,317 - $50,529
266 Added 61.86%
696 $97,000
Q2 2019

Aug 09, 2019

SELL
$157.85 - $183.09 $18,152 - $21,055
-115 Reduced 21.1%
430 $0
Q1 2019

May 10, 2019

BUY
$89.33 - $163.65 $44,754 - $81,988
501 Added 1138.64%
545 $0
Q4 2018

Feb 08, 2019

SELL
$81.94 - $139.71 $1,556 - $2,654
-19 Reduced 30.16%
44 $4,000
Q3 2018

Nov 09, 2018

BUY
$138.11 - $169.04 $3,452 - $4,226
25 Added 65.79%
63 $0
Q2 2018

Aug 10, 2018

BUY
$140.36 - $175.76 $1,965 - $2,460
14 Added 58.33%
38 $0
Q1 2018

May 11, 2018

BUY
$152.15 - $192.33 $2,130 - $2,692
14 Added 140.0%
24 $0
Q4 2017

Feb 09, 2018

BUY
$60.72 - $167.34 $607 - $1,673
10
10 $0

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $340M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Pnc Financial Services Group, Inc. Portfolio

Follow Pnc Financial Services Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.